Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- gp100 in metastatic melanoma
NCT00094653Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2004
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Sep 2004; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00094653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094653.